Day: July 23, 2020

Form 8.3 – HWSI Realisation Fund Limited

Written by Customer Service on July 23, 2020. Posted in Mergers And Acquisitions.

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should...

OptimizeRx Sets Second Quarter 2020 Conference Call for Wednesday, August 5, 2020 at 4:30 p.m. ET

Written by Customer Service on July 23, 2020. Posted in Public Companies.

ROCHESTER, Mich., July 23, 2020 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, will hold a conference call on Wednesday, August 5, 2020 at 4:30 p.m. Eastern time to discuss results for the second quarter ended June 30, 2020. The financial results will be issued in a press release prior to the call.OptimizeRx management will host the call, followed by a question and answer period.Date: Wednesday, August 5, 2020Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)Toll-free dial-in number: 1-866-248-8441International dial-in number: 1-323-289-6576Conference ID: 1161129Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting...

Verrica Pharmaceuticals Announces Dr. Lawrence Eichenfield Joins Board of Directors

Written by Customer Service on July 23, 2020. Posted in Public Companies.

– Leading pediatric dermatologist brings significant expertise in the treatment of skin diseases to help inform development of the Company’s product candidates –WEST CHESTER, Pa., July 23, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Dr. Lawrence Eichenfield, Chief of Pediatric and Adolescent Dermatology, Rady Children’s Hospital, San Diego, CA, is joining the Company’s Board of Directors (the “Board”), effective August 1, 2020. Dr. Eichenfield will replace Dr. Gary Goldenberg who will be stepping down from the Board to assume the role of Verrica’s Chief Medical Officer, which the Company announced separately today.“Dr. Eichenfield’s research has shaped the field...

APPlife Digital Solutions, Inc. Announces Engagement of Investment Banking Firm Carter, Terry & Company

Written by Customer Service on July 23, 2020. Posted in Public Companies.

SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) — APPlife Digital Solutions, Inc. (OTCQB: ALDS) (“APPlife”, the Company”), a business incubator and portfolio manager that invests in and creates e-commerce and cloud-based solutions, announced today that it has retained the services of Atlanta-based investment banking firm Carter, Terry & Company (“Carter, Terry”) to assist in raising new capital, as well as fund the Company’s continuing general operations. “Engaging Carter, Terry & Company is the next important step in supporting the execution of our business plan, as well as to assist in broadening APPlife’s brand through potential strategic acquisitions and partnerships,” stated Matt Reid, CEO of APPlife. “Carter, Terry, along with our financial advisory partner Maxim Group, have previously worked simultaneously on a...

WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

Written by Customer Service on July 23, 2020. Posted in Public Companies.

VANCOUVER, British Columbia, July 23, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce that Moleculin Biotech Inc. (“Moleculin”), the company that sublicenses the compound WP1122 to WPD for 29 countries mainly in Europe, announced that a second round of independent laboratory testing has confirmed the antiviral activity of WP1122 against coronavirus.Moleculin’s July 21, 2020 press release states, “Moleculin contracted with IIT Research Institute (an affiliate of the Illinois Institute of Technology, “IITRI”) for additional in vitro testing of its drug candidate, WP1122, in development as a possible treatment for COVID-19. The testing involved a cell viability assay in the VERO E6 cell line infected with SARS-CoV-2...

Verizon Communications to report earnings July 24, 2020

Written by Customer Service on July 23, 2020. Posted in Public Companies.

BASKING RIDGE, N.J., July 23, 2020 (GLOBE NEWSWIRE) — Verizon Communications Inc. (NYSE, Nasdaq: VZ) will report second quarter 2020 earnings on Friday, July 24.The company will present results on a webcast beginning at 8:30 a.m. Eastern Time. Access instructions and presentation materials, including Verizon’s earnings news release and financial tables, will be available at 7:30 a.m. on Verizon’s Investor Relations website, https://www.verizon.com/about/investors.Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is celebrating its 20th year as one of the world’s leading providers of technology, communications, information and entertainment products and services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $131.9 billion in 2019. The company offers...

Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes

Written by Customer Service on July 23, 2020. Posted in Public Companies.

– Dr. Gary Goldenberg appointed Chief Medical Officer; Dr. Brad Catalone assumes the role of Head of Drug Development –– New leadership strengthens expertise in Clinical, Chemistry, Manufacturing, and Controls (CMC), and Regulatory Affairs –WEST CHESTER, Pa., July 23, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced key appointments to its drug development team.Current Board of Directors (the “Board”) member Dr. Gary Goldenberg, a renowned thought leader in the field of dermatology, is stepping down to become Verrica’s Chief Medical Officer, effective August 1, 2020. Verrica announced separately today that Dr. Lawrence Eichenfield is joining the Board on August 1, 2020,...

Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020

Written by Customer Service on July 23, 2020. Posted in Public Companies.

SAN CARLOS, Calif., July 23, 2020 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT.To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 7875997. The live webcast can be accessed in the Investors section of the Company’s website at www.iovance.com. The archived webcast will be available for one year.About Iovance Biotherapeutics, Inc.Forward-Looking StatementsCertain matters discussed in this press release are “forward-looking...

Amerigo Reports Q2-2020 Production Results and Provides Operational Update

Written by Customer Service on July 23, 2020. Posted in Public Companies.

VANCOUVER, British Columbia, July 23, 2020 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (“Amerigo” or the “Company”) (TSX: ARG) announced today Q2-2020 production results from Minera Valle Central (“MVC”), the Company’s 100% owned operation located near Rancagua, Chile.MVC produced 12.97 million pounds (“M lbs”) of copper at a cash cost of US$1.72/lb per pound, and 0.35 M lbs of molybdenum. In Q2-2020, MVC’s copper production from fresh and Cauquenes tailings increased 20% compared to Q1-2020.Copper production results are in line with the Company’s 2020 guidance (refer to our news release of February 19, 2020) where the Company announced a reduction in Cauquenes tonnage processing to approximately 40,000 tonnes per day (“TPD”) through H1-2020 in response to drought conditions then present in central...

American National Bankshares Reports Second Quarter Earnings

Written by Customer Service on July 23, 2020. Posted in Public Companies.

DANVILLE, Va., July 23, 2020 (GLOBE NEWSWIRE) — American National Bankshares Inc. (NASDAQ: AMNB) (“American National” or the “Company”) today reported second quarter 2020 earnings of $5.5 million, or $0.50 per diluted common share. Those results compare to a net loss of $1.2 million, or ($0.11) per diluted common share, during the same quarter in the prior year, and net income of $8.5 million, or $0.77 per diluted common share, recognized for the first quarter of 2020. Earnings for the first six months of 2020 were $14.0 million, or $1.28 per diluted common share, compared to $4.8 million, or $0.48 per diluted common share for the same period of 2019. Earnings for the second quarter and six months of 2019 were impacted by $10.9 million and $11.3 million, respectively, in merger related expenses.President and Chief Executive Officer...

Day: July 23, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals